mRNA‐Engineered CD5‐CAR‐γδT CD5‐ Cells for the Immunotherapy of T‐Cell Acute Lymphoblastic Leukemia
Advanced Science · 2024-09 · 11 (35)
DOI: 10.1002/advs.202400024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 16.07.2024. Verfasst von Zhixiong Zhu und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Biotherapy and Cancer Center, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu…. Hauptthemen laut MEDLINE: Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Immunotherapy, Adoptive, RNA, Messenger, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Sichuan University, National Key Research and Development Program of China.
Abstract (Originalsprache)
Clinical trials of Chimeric Antigen Receptor T‐cell (CAR‐T) therapy have demonstrated remarkable success in treating both solid tumors and hematological malignancies. Nanobodies (Nbs) have emerged as promising antigen‐targeting domains for CARs, owing to their high specificity, robust stability, and strong affinity, leading to significant advancements in the field of Nb‐CAR‐T. In the realm of T‐cell acute lymphoblastic leukemia (T‐ALL) targets, CD5 stands out as a potentially excellent candidate for T‐cell‐based CAR therapy, due to its distinct expression on the surface of malignant T‐ALL cells. To mitigate graft‐versus‐host disease associated with allogeneic CAR‐T, γδT cells are selected and stimulated from peripheral blood mononuclear cells, and γδT cells are engineered via CRISPR/Cas9 to eliminate fratricide, enabling the creation of fratricide‐resistant CAR‐γδT CD5− cells. In vitro transcribed (IVT) mRNA is used to construct CAR‐T, presenting a safer, faster, and cost‐effective method compared to traditional viral vector approaches. In this study, a CD5‐VHH library is constructed, and specific CD5‐nanobodies are screened for subsequent use in CD5‐CAR‐γδT CD5− therapy. IVT‐mRNA‐CD5‐CAR‐γδT CD5− cells exhibited favorable functional characteristics and demonstrated antitumor efficacy against malignant T cell lines, underlining the potential for advancing mRNA‐CD5‐CAR‐γδT CD5− therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Biotherapy and Cancer Center, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
- Department of Hematology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
- Frontiers Medical Center, Tianfu Jincheng Laboratory, Chengdu, 610212, China.
ORCID-Profile: Aiping Tong
Förderung
- National Natural Science Foundation of China
- Sichuan University
- National Key Research and Development Program of China
- Frontiers Medical Center, Tianfu Jincheng Laboratory Foundation
- Major scientific and technological achievements transformation project, Ningxia Hui Autonomous Region
- CAMS Innovation Fund for Medical Science (CIFMS)
Zitieren
APA
Zhu, Z., Li, H., Lu, Q., Zhang, Z., Li, J., Wang, Z., Yang, N., Yu, Z., Yang, C., Chen, Y., Lu, H., Wang, W., Niu, T., Nie, C., & Tong, A. (2024). mRNA‐Engineered CD5‐CAR‐γδT CD5‐ Cells for the Immunotherapy of T‐Cell Acute Lymphoblastic Leukemia. Advanced Science, 11(35). https://doi.org/10.1002/advs.202400024
Vancouver
Zhu Z, Li H, Lu Q, Zhang Z, Li J, Wang Z, et al. mRNA‐Engineered CD5‐CAR‐γδT CD5‐ Cells for the Immunotherapy of T‐Cell Acute Lymphoblastic Leukemia. Advanced Science. 2024;11(35). doi:10.1002/advs.202400024
BibTeX
@article{Zhu2024,
author = {Zhu, Zhixiong and Li, Hexian and Lu, Qizhong and Zhang, Zongliang and Li, Jia and Wang, Zeng and Yang, Nian and Yu, Zhengyu and Yang, Chen and Chen, Yongdong and Lu, Huaqing and Wang, Wei and Niu, Ting and Nie, Chunlai and Tong, Aiping},
title = {mRNA‐Engineered CD5‐CAR‐γδT CD5‐ Cells for the Immunotherapy of T‐Cell Acute Lymphoblastic Leukemia},
journal = {Advanced Science},
year = {2024},
volume = {11},
number = {35},
doi = {10.1002/advs.202400024}
}
EUVIMED